Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Insilico Medicine, an AI Drug Company, Files for Hong Kong IPO

publication date: Apr 4, 2024

Insilico Medicine, an AI drug discovery-development company based in Hong Kong and New York, has completed an initial filing for a Hong Kong IPO. Insilico has developed several platforms that use generative AI to analyze biology, chemistry and clinical trials for next-gen AI systems. Formed in 2014, Insilico develops products for its own portfolio and out-licenses other candidates, while retaining their intellectual property. Two years ago, the company bragged that it needed only 30 months to move its lead drug from discovery to clinical trials at a cost of $2.5 million. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here